3 recruiting, 2 terminated, 2 unknown, 1 completed. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 3, Terminated 2, Unknown 2, Completed 1, Withdrawn 1 |
| Phase 1 | 4 | Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow TIL: new trials by email Literature Review of TIL trials Research Report on TIL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. Lifileucel - Endometrial Cancer | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 60 | 2024-10-29 | 2025-10-30 |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers E7 TCR-T cells, Aldesleukin - Cervical Cancer, Throat Cancer | Phase 2 | Recruiting | Christian Hinrichs | 20 | 2023-03-07 | 2026-10-28 |
| OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial) cyclophosphamide, fludarabine, IL-2 (Proleukin) - Ovarian Cancer Metastatic | Phase 1 / Phase 2 | Withdrawn | Immetacyte Ltd | 2020-07-01 | 2020-12-16 | |
| Immunotherapy for the Treatment of Advanced Solid Tumor TIL, Aldesleukin, Cyclophosphamide - Recurrence Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Unknown | Tongji Hospital | 40 | 2020-04-28 | 2024-08-13 |
| Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients Fludarabine, Cyclophosphamide, TIL - Malignant Melanoma Stage IV | Phase 2 | Unknown | Sheba Medical Center | 30 | 2017-06-05 | 2023-01-26 |
| TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment Cyclophosphamide, Fludarabine, Tumour Infiltrating Lymphocytes - Metastatic Melanoma | Phase 2 | Terminated | The Christie NHS Foundation Trust | 2 | 2014-03-01 | 2023-04-20 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Fludarabine, Cyclophosphamide, Young TIL - Cervical Cancer, Oropharyngeal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2012-04-13 | 2018-03-07 |
| Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes - Metastatic Melanoma, Skin Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2011-05-01 | 2015-01-27 |
Anus Neoplasms (3) · Melanoma (3) · Oropharyngeal Neoplasms (3) · Penile Neoplasms (3) · Uterine Cervical Neoplasms (3) · Vaginal Neoplasms (3) · Neoplasm Metastasis (2) · Vulvar Neoplasms (2) · Endometrial Neoplasms (1) · Papillomavirus Infections (1) · Recurrence (1) · Skin Neoplasms (1)
Christian Hinrichs (2) · National Cancer Institute (NCI) (2) · Immetacyte Ltd (1) · Iovance Biotherapeutics, Inc. (1) · Sheba Medical Center (1) · The Christie NHS Foundation Trust (1) · Tongji Hospital (1)
United States (5) · United Kingdom (2) · China (1) · Israel (1)
Christian S Hinrichs, MD (2) · Steven A Rosenberg, M.D. (2) · Fiona Thistlethwaite, PhD, MRCP (1) · Hui Wang, MD (1) · Paul Lorigan, MD (1) · Robert E Hawkins, MD (1)
PMID 25823737, PMID 30714987, PMID 33990415
2019 (1), U01CA287904 (1)